Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/18/2025

Thyroid Disorders

Introduction to Hashimoto's Thyroiditis

  • Hashimoto's thyroiditis is an autoimmune thyroid disorder characterized by the combination of elevated TSH, low T4, and positive thyroid peroxidase (TPO) antibodies, requiring thyroid hormone replacement therapy, and is the most common cause of hypothyroidism worldwide 1, 2, 3
  • The condition leads to progressive destruction of thyroid tissue, gradual decline in thyroid hormone production, and eventual thyroid failure, necessitating lifelong hormone replacement 3

Diagnosis and Confirmation

  • The laboratory pattern of high TSH, low T4, and elevated TPO antibodies is diagnostic of overt primary hypothyroidism with an autoimmune etiology (Hashimoto's thyroiditis) 3
  • Thyroid function tests should be repeated if TSH is mildly elevated (4.5-10 mIU/L), but not if TSH >10 mIU/L with low T4, and central hypothyroidism should be ruled out if TSH is low or normal with low T4, considering pituitary dysfunction 2, 3, 4
  • The American College of Clinical Endocrinologists recommends confirming elevated TSH and T4 with repeat testing, checking thyroid antibodies, and considering testing on an alternative laboratory platform if results seem discordant 1

Treatment and Management

  • Levothyroxine therapy should be initiated at a dose of 1.6 mcg/kg/day for young, healthy adults, and 25-50 mcg/day for elderly or patients with cardiac disease, with monitoring and adjustment of treatment by checking TSH and free T4 after 6-8 weeks, targeting TSH in the lower half of the reference range (0.4-2.5 mIU/L) 4, 5
  • The Endocrine Society and the American Association of Clinical Endocrinologists recommend adjusting the dose in 12.5-25 mcg increments until the target TSH is reached, with annual monitoring once stable 5, 4
  • Levothyroxine should be taken on an empty stomach, 30-60 minutes before breakfast, and avoided with medications that affect absorption 5

Monitoring and Complications

  • Patients should be monitored for transition from thyroiditis, and for complications such as severe untreated hypothyroidism progressing to myxedema coma, requiring hospitalization and intravenous treatment 2, 4
  • Common symptoms of Hashimoto's thyroiditis include fatigue, weight gain, cold intolerance, constipation, hair loss, and depression, associated with higher TPO antibody levels 1
  • The American Society of Clinical Oncology recommends continuing immune checkpoint inhibitors if this is the cause, unless symptoms are severe, and conservative management is sufficient during the thyrotoxic phase, with beta-blockers for symptomatic relief and monitoring of thyroid function every 2-3 weeks 1, 4
  • Overtreatment risks include iatrogenic hyperthyroidism, cardiac arrhythmias, and bone loss, occurring in 14-21% of treated patients, resulting in subclinical hyperthyroidism 5
  • Inadequate monitoring can lead to failure to check thyroid function tests at appropriate intervals, and adrenal insufficiency should be suspected and treated with steroids prior to thyroid hormone to avoid adrenal crisis 5, 1